title: A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer.
abstract: OBJECTIVE
  There is an urgent need for new agents with activity in platinum- and taxane-resistant epithelial ovarian cancer. Exatecan mesylate is a novel topoisomerase I inhibitor with potent activity against ovarian cancer in vitro. A multicentre phase IIA study was conducted in patients with platinum- and taxane-resistant epithelial ovarian cancer.
  
  
  METHODS
  Fifty-seven patients with bidimensionally measurable ovarian cancer, previously exposed to platinum and taxanes, whose disease had relapsed within 6 months of platinum-containing chemotherapy were randomised to one of two intravenous schedules of exatecan mesylate; 0.3 mg/m(2) daily for 5 days every 3 weeks (Arm A) or 2.1 mg/m(2) weekly for 3 weeks out of 4 (Arm B).
  
  
  RESULTS
  There were no responses in the weekly arm and a radiological response rate of 5.3% (95% CI 0.3-21.8%) in the daily arm. Principal toxicities were myelosuppression and emesis. Grade 3/4 neutropenia occurred in 29% of patients in Arm A and 6% patients in Arm B. Seventy-one percent of patients in Arm A required red cell transfusions while on treatment.
  
  
  CONCLUSIONS
  Exatecan is well tolerated in this poor prognosis group of patients but only has modest single agent activity when administered in a daily regimen.
authors.affiliation: Cancer Research UK Deparment of Medical Oncology, Christie Hospital, M20 4BX, UK.
authors.forename: A
authors.initials: A
authors.lastname: Clamp
authors.forename: M
authors.initials: M
authors.lastname: Adams
authors.forename: R
authors.initials: R
authors.lastname: Atkinson
authors.forename: E
authors.initials: E
authors.lastname: Boven
authors.forename: A H
authors.initials: AH
authors.lastname: Calvert
authors.forename: A
authors.initials: A
authors.lastname: Cervantes
authors.forename: T
authors.initials: T
authors.lastname: Ganesan
authors.forename: J
authors.initials: J
authors.lastname: Lotz
authors.forename: P
authors.initials: P
authors.lastname: Vasey
authors.forename: P
authors.initials: P
authors.lastname: Cheverton
authors.forename: G C
authors.initials: GC
authors.lastname: Jayson
mesh_terms: D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology; D001952:Bridged-Ring Compounds / Q000008:administration & dosage; D002166:Camptothecin / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives*; D004334:Drug Administration Schedule; D018432:Drug Resistance, Multiple; D019008:Drug Resistance, Neoplasm; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D043823:Taxoids / Q000008:administration & dosage; D059004:Topoisomerase I Inhibitors
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D001952:Bridged-Ring Compounds; D004791:Enzyme Inhibitors; D009944:Organoplatinum Compounds; D043823:Taxoids; D059004:Topoisomerase I Inhibitors; C080625:taxane; C095887:exatecan; D002166:Camptothecin